Trial Profile
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) and Evaporative Dry Eye Disease (DED)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs AZR-MD-001 (Primary)
- Indications Dry eyes; Meibomian gland dysfunction
- Focus Therapeutic Use
- Sponsors Azura Ophthalmics
- 20 Apr 2023 According to an Azura Ophthalmics media release, data from this study will be featured at the upcoming Annual Meetings for the Association for Research in Vision and Ophthalmology (ARVO) and in the American Society of Cataract and Refractive Surgery (ASCRS) 2023.
- 09 Dec 2022 Primary endpoint has been met. (Ocular Surface Disease Index (OSDI) score), according to an Azura Ophthalmics media release.
- 09 Dec 2022 Results published in the Azura Ophthalmics Media Release.